Job Seekers, Welcome to Regulatory Career Connections
Search Filters
Use this area to filter your search results. Each filter option allows for multiple selections.
Search Results: 75 Jobs
Save Agent
Loading... Please wait.
Lipocine Inc.

Salt Lake City, Utah

Ortho Molecular Products Logo
Ortho Molecular Products

Stevens Point, Wisconsin

NEW! NEW!
Blaze Bioscience, Inc. Logo
Blaze Bioscience, Inc.

Seattle, Washington

NEW! NEW!
Cytokinetics, Inc.

San Francisco, California

NEW! NEW!
MedicaSafe Logo
MedicaSafe

Nationwide

MASSBIOLOGICS

Mattapan, Massachusetts

Meridian Bioscience

Cincinnati, Ohio

Meridian Bioscience

Nationwide

Sumitomo Pharma Oncology Inc

Malborough, Massachusetts

Transonic Systems Inc Logo
Transonic Systems Inc

Ithaca, New York

Blistex Inc

Oak Brook, Illinois

Mirum Pharmaceuticals

Nationwide

Spacelabs Healthcare

Snoqualmie, Washington

Certara

Remote, North Carolina

Certara

Raleigh, North Carolina

PARI Respiratory Equipment Logo
PARI Respiratory Equipment

Midlothian, Virginia

CSL Behring

King of Prussia, Pennsylvania

Lumos Pharma, Inc. Logo
Lumos Pharma, Inc.

Ames, Iowa

Lexicon Pharmaceuticals Logo
Lexicon Pharmaceuticals

Nationwide

United Therapeutics Corporation

Manchester, New Hampshire

The University of Vermont Medical Center

Burlington, Vermont

NEW! NEW!
George Mason University

Fairfax, Virginia

NEW! NEW!
Loading... Please wait.
Expand Show Other Jobs
Job Saved Save Job
Association Logo
Regulatory Affairs Professional
Lipocine Inc.
Email Print
About Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company focused on neuroendocrine and metabolic disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: LPCN 1148, LPCN 1144, LPCN 1111, LPCN 1107 and oral neuroactive steroids including LPCN 1154 and LPCN 2101. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the management of symptoms associated with liver cirrhosis. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a Phase 2 clinical study demonstrating potential utility in the treatment of non-cirrhotic NASH. LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once or twice daily, LPCN 1111 met primary and secondary endpoints. LPCN 1107 is potentially the first oral hydroxyprogesterone caproa...te product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. Neuroactive steroids are currently being evaluated including LPCN 1154 for the potential treatment of postpartum depression and LPCN 2101 for the potential treatment of epilepsy. For more information, please visit www.lipocine.com.
Connections working at Lipocine Inc.
https://regulatorycareers.raps.org/jobs/17182802/regulatory-affairs-professional
Loading. Please wait.
Powered By Naylor Association Solutions
For assistance please call 888.491.8833 or e-mail candidatesupport@naylor.com